AUS
NZ
UK
CA
USA
IND
Imagion Biosystems Limited (ASX:IBX), a company specializing in medical imaging technology, has applied for the Quotation of 49,346,051 newly issued ordinary fully paid shares on the ASX. This follows the completion of a Placement initially announced on 25 June 2026. The shares were issued on 30 June 2026 at $0.012 each and are now set for trading after the submission of an Appendix 2A on 2 July 2026. The capital raise, earlier disclosed via an Appendix 3B, increases the company's total quoted ordinary shares to 539,936,290. Stakeholders in the medical technology sector are likely monitoring how the company plans to utilize the proceeds from this placement.
Key Points
- Company: Imagion Biosystems Limited (ASX:IBX)
- Application for quotation of 49,346,051 new ordinary fully paid shares via Appendix 2A lodged on 2 July 2026
- Shares issued on 30 June 2026 at $0.012 per share, raising gross proceeds calculable at that price
- Total quoted ordinary shares after quotation: 539,936,290
- Placement was part of a transaction previously notified via Appendix 3B on 25 June 2026
- No additional securities issuances are expected to complete this transaction, per the filing
- Investors should monitor disclosures regarding the use of placement proceeds
Imagion Biosystems Completes Placement with 49.3 Million Shares Issued at $0.012
Imagion Biosystems Limited has formally applied for the quotation of 49,346,051 new ordinary fully paid shares, concluding a placement process first announced in an Appendix 3B lodged on 25 June 2026. The shares were issued at AUD $0.012 each on 30 June 2026, with the quotation application submitted to the ASX on 2 July 2026.
The placement was conducted in Australian dollars with cash consideration. Based on the issue price and number of shares, gross proceeds approximate $592,152, although the company did not specify the total amount raised in this filing. Investors seeking precise net proceeds or intended fund usage should consult any additional company disclosures related to this transaction.
From Appendix 3B on 25 June 2026 to Quotation Application
The process began with an Appendix 3B lodged on 25 June 2026 at 9:29 AM titled "New - Proposed issue of securities - IBX," which informed the market of the planned securities issuance as part of a placement or similar transaction. The subsequent Appendix 2A filed on 2 July 2026 confirms the actual issuance and requests official quotation of the new shares.
The latest filing confirms no further securities will be issued to complete this transaction, indicating the placement is fully executed. This sequence aligns with standard ASX Listing Rules procedures for capital raisings.
Total Ordinary Shares Increase to 539,936,290 After Quotation
Following admission to trading of the 49,346,051 new shares, Imagion Biosystems’ total quoted ordinary fully paid shares will total 539,936,290, as detailed in Part 4 of the Appendix 2A. This increase reflects the dilutive effect of the placement on existing shareholders, a typical outcome in capital raisings at this price point.
In addition to ordinary shares, the company has 330,833,334 quoted Options expiring 13 December 2027 (IBXO) listed on the ASX. Together, these securities form a significant portion of the company’s Capital Structure. Investors interested in dilution should review the full securities schedule in the filing.
Diverse Unquoted Securities Highlight Complex Capital Structure
Imagion Biosystems holds numerous unquoted securities, including over a dozen classes of options with exercise prices ranging from $0.012 to $3.488 and expiry dates between August 2026 and May 2030. These reflect the company’s history of capital raisings, employee incentives, and financing transactions.
Noteworthy unquoted options include 26,250,000 expiring 21 September 2028 at $0.04 (IBXAA), 12,254,902 expiring 10 September 2027 at $0.04284 (IBXABB), and 10,600,177 expiring 23 April 2029 at $0.0297 (IBXABF). The company also has 2,780,000 unquoted convertible notes (IBXAAQ). This extensive unquoted register underscores the potential for further dilution if instruments are exercised or converted.
Five Classes of Performance Rights Reflect Ongoing Incentive Programs
Imagion Biosystems has five classes of outstanding performance rights: 975,000 Class A (IBXAAY), 375,000 Class B (IBXAAZ), 500,000 Class C (IBXABA), 2,200,000 Class D (IBXAG), and 4,000,000 Class E (IBXAH), all unquoted.
These performance rights typically serve as long-term incentives for executives and key staff, with vesting tied to milestones or service periods. The company did not disclose specific vesting conditions or hurdles in this filing. Interested shareholders may consult recent remuneration reports or meeting notices for details.
Placement Price Aligns with Some Low-Exercise-Price Options
The $0.012 placement price matches the exercise price of certain options, such as 4,700,000 options expiring 29 May 2030 at $0.012 (IBXABE). This alignment may interest investors evaluating the valuation implications of the placement.
Conversely, other option series carry exercise prices well above the placement price, including $0.90, $1.12, $1.68, and $3.488, which are significantly out of the money relative to $0.012. The company did not comment on these legacy options. The immediate share price impact of the quotation was not evident from public data.
Company Confirms No Further Securities to Complete Placement
The Appendix 2A confirms no additional securities will be issued to complete this transaction, indicating the placement is fully subscribed with no shortfall or staged components remaining.
This confirmation removes uncertainty often associated with partially completed capital raisings. With the placement finalized and quotation application lodged, investor focus will likely turn to how Imagion Biosystems plans to deploy the proceeds and advance operational or clinical milestones. The filing does not disclose intended use of funds.
Expanded Share Register Enhances Future Funding Potential
With total ordinary shares increasing to 539,936,290, Imagion Biosystems has significantly expanded its shareholder base. For a capital-intensive medical imaging technology company, access to Equity Capital Markets is vital for Research and Development, regulatory approvals, and commercialization.
The successful placement at $0.012 per share indicates investor interest at this price. Market attention will likely focus on upcoming operational updates detailing use of proceeds, project timelines, and potential catalysts. The next milestone is the official commencement of trading of the new shares upon ASX admission.
Convertible Notes Add Complexity to Capital Structure
The filing reveals 2,780,000 convertible notes (IBXAAQ) among unquoted instruments, which may convert into equity under certain terms, potentially diluting shareholders further.
The company did not disclose conversion terms, Interest Rate, Maturity date, or conversion price for these notes in this filing. Investors should review the latest Annual Report, half-year results, or other disclosures to understand full dilution implications. The complete set of options, performance rights, and convertible instruments represents a key consideration for modeling the company’s capital structure going forward.
